Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024
Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024
Soligenix公佈成立歐洲醫療顧問委員會,爲提供額外的醫療/臨床戰略指導;HyBryte在CTCL的第三階段臨床研究將於2024年啓動。
Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024
Soligenix公佈成立歐洲醫療顧問委員會,以提供額外的醫療/臨床戰略指導;HyBryte在CTCL的第三階段臨床研究將於2024年啓動。